Table of Contents
ISRN Gastroenterology
Volume 2012, Article ID 969015, 4 pages
http://dx.doi.org/10.5402/2012/969015
Research Article

Utility of Analgesic and Anxiolytic Medication Dose during Colonoscopy in Identifying Patients with Irritable Bowel Syndrome

1Medical Center Of Central Georgia, 777 Hemlock Street, Macon, GA 31201, USA
2Valley Gastroenterology Associates, 4860 McLeod Dr Ste A, Saginaw, MI 48604, USA
3Synergy Medical Education Alliance, 1000 Houghton Avenue, Saginaw, MI 48602, USA
4Synergy Medical Education Alliance, 1000 Houghton Avenue, Saginaw, MI 40602, USA

Received 28 September 2011; Accepted 27 October 2011

Academic Editor: W. A. Meier-Ruge

Copyright © 2012 Enoch Lule et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Research question. This paper was done to answer the question on whether patients with IBS require higher analgesic or anxiolytic doses during colonoscopy. Setting. Gastroenterology practice in Michigan, USA. Methods. We reviewed the charts of patients following up with a US based gastroenterology practice. We collected data on whether or not they had IBS, and collected data on analgesic and anxiolytic requirement during colonoscopy. Results. 336 patients were included in the trial. 206 did not have IBS while 130 had a previous diagnosis of IBS. 234 were female (67.2%). When comparing patients who have IBS to those without IBS, we identified no statistically significant difference in midazolam dose (5.5 mg versus 5.5 mg), fentanyl dose ( 117 mg versus 112 mg) or meperidine dose (69 mg versus 69 mg). The lack of differences in medication doses used remained when we controlled for sex, prior analgesic use, and prior abdominal surgery. Conclusion. Dose of analgesic or anxiolytic used during colonoscopy cannot be used to identify patients with IBS.